Last quarter (Q ), Turning Point Therapeutics's total revenue was $119.00K, a decrease of -97.70% from the same quarter last year. In Q, Turning Point Therapeutics's net income was $-123.09M. See Turning Point Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	$ 1.01M	$ 30.83M	$ 25.00M	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 345.60M	$ 268.83M	$ 186.84M	$ 77.72M	$ 25.64M	$ 16.73M
Operating Income	$ -344.59M	$ -238.00M	$ -161.84M	$ -77.72M	$ -25.64M	$ -16.73M
Net Non Operating Interest Income Expense	-	-	-	-	$ 856.00K	-
Other Income Expense	$ 2.29M	$ 1.45M	$ 4.54M	$ 5.59M	$ 855.00K	$ 136.00K
Pretax Income	$ -342.31M	$ -236.55M	$ -157.29M	$ -72.13M	$ -24.79M	$ -16.59M
Tax Provision	-	-	-	-	$ 1.00K	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -342.31M	$ -236.55M	$ -157.29M	$ -72.13M	$ -24.79M	$ -16.59M
Basic EPS	$ -6.90	$ -4.80	$ -3.85	$ -2.99	$ -1.66	$ -1.11
Diluted EPS	$ -6.90	$ -4.80	$ -3.85	$ -2.99	$ -1.66	$ -1.11
Basic Average Shares	$ 198.24M	$ 49.26M	$ 40.84M	$ 24.12M	$ 14.94M	$ 14.94M
Diluted Average Shares	$ 198.24M	$ 49.26M	$ 40.84M	$ 24.12M	$ 14.94M	$ 14.94M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 345.60M	$ 268.83M	$ 186.84M	$ 77.72M	$ 25.64M	$ 16.73M
Net Income From Continuing And Discontinued Operation	$ -342.31M	$ -236.55M	$ -157.29M	$ -72.13M	$ -24.79M	$ -16.59M
Normalized Income	$ -342.31M	$ -236.55M	$ -157.29M	$ -72.13M	$ -24.79M	$ -16.59M
Interest Expense	-	-	-	-	-	-
EBIT	$ -344.59M	$ -238.00M	$ -161.84M	$ -77.72M	$ -25.64M	$ -16.73M
EBITDA	$ -339.54M	$ -234.03M	$ -159.44M	$ -76.14M	$ -25.50M	$ -16.67M

Currency in USD

Turning Point Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing